Loading…
Loading grant details…
| Funder | National Institutes of Health |
|---|---|
| Recipient Organization | Not specified |
| Country | USA |
| Start Date | Dec 30, 2024 |
| End Date | Aug 19, 2026 |
| Duration | 597 days |
| Number of Grantees | 1 |
| Data Source | Grants.gov |
| Grant ID | 100dd27f-4cc8-49e1-89b9-24602921eda6 |
This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD.
This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes.
The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.
To be determined
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant